文献速递血管炎

英国多中心服务评估:每周托珠单抗治疗巨细胞动脉炎停药后复发情况

Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该多中心服务评估分析了英国40个中心336例接受每周皮下托珠单抗治疗中位12个月的巨细胞动脉炎患者,停药后6、12、24个月复发率分别为21.4%、35.4%、48.6%,33.6%的复发为大复发。既往治疗期间曾复发、停药时未缓解及影像学大血管受累者复发时间更短。

要点

  • 停药后24个月近半数患者复发,复发时需将泼尼松龙剂量中位增至20 mg/日。
  • 既往治疗期间曾复发、停药时未缓解及影像学大血管受累者复发更早。
  • 作者认为对这些患者可考虑延长托珠单抗使用或复发时重复治疗。

核心结论

  • 高达半数巨细胞动脉炎患者停用每周托珠单抗后复发,常需大幅增加泼尼松龙剂量,三分之一的复发为大复发。
  • 作者认为对这些患者可考虑延长托珠单抗使用或复发时重复治疗。

研究设计与样本

  • 多中心服务评估,分析英国40个中心336例接受每周皮下托珠单抗治疗的巨细胞动脉炎患者停药后复发情况。
  • 采用对数秩检验比较复发时间的差异。

主要发现

  • 患者接受每周皮下托珠单抗治疗中位12(IQR 12–17)个月,停药时泼尼松龙剂量中位2(IQR 0–5)mg/日。
  • 停药后6、12、24个月分别有21.4%、35.4%、48.6%的患者复发,复发时泼尼松龙剂量需增至中位20(IQR 10–40)mg/日。
  • 33.6%的复发患者按EULAR定义为大复发。
  • 既往每周托珠单抗治疗期间也曾复发者(P=0.0017)、停药时未达缓解者(P=0.0036)及影像学显示大血管受累者(P=0.0296)复发时间更短。
  • 年龄≥65岁、性别、GCA相关视力丧失、每周托珠单抗治疗时长、托珠单抗减量、泼尼松龙剂量及传统合成改善病情抗风湿药使用与复发时间无关。

临床怎么用

  • 作者认为对这些患者可考虑延长托珠单抗使用或复发时重复治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The National Health Service in England funds 12 months of weekly s.c. tocilizumab (qwTCZ) for patients with relapsing or refractory GCA. During the coronavirus disease 2019 (COVID-19) pandemic, some patients were allowed longer treatment. We sought to describe what happened to patients after cessation of qwTCZ. METHODS: Multicentre service evaluation of relapse after stopping qwTCZ for GCA. The log-rank test was used to identify significant differences in time to relapse. RESULTS: A total of 336 GCA patients were analysed from 40 centres, treated with qwTCZ for a median [interquartile range (IQR)] of 12 (12-17) months. At time of stopping qwTCZ, median (IQR) prednisolone dose was 2 (0-5) mg/day. By 6, 12 and 24 months after stopping qwTCZ, 21.4%, 35.4% and 48.6%, respectively, had relapsed, requiring an increase in prednisolone dose to a median (IQR) of 20 (10-40) mg/day. 33.6% relapsers had a major relapse as defined by EULAR. Time to relapse was shorter in those that had previously also relapsed during qwTCZ treatment (P = 0.0017), in those not in remission at qwTCZ cessation (P = 0.0036) and in those with large vessel involvement on imaging (P = 0.0296). Age ≥65 years, gender, GCA-related sight loss, qwTCZ treatment duration, TCZ taper, prednisolone dosing and conventional synthetic DMARD use were not associated with time to relapse. CONCLUSION: Up to half our patients with GCA relapsed after stopping qwTCZ, often requiring a substantial increase in prednisolone dose. One-third of relapsers had a major relapse. Extended use of TCZ or repeat treatment for relapse should be considered for these patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Quick V, Abusalameh M, Ahmed S, et al. Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England. Rheumatology (Oxford). 2024. PMID: 37952183. doi:10.1093/rheumatology/kead604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。